Clinical Trial Update: Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with or without ipilimumab in patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Carcinoma
• Pulmonary Neuroendocrine Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED